Advanced in Leukemia

Bing X. Xu

Xiamen, CN 
Advanced in Leukemia
Xiamen, CN 
OverviewLocationsClinical Research

Overview

Bing Xu practices in Xiamen, China. Mr. Xu is rated as an Advanced expert by MediFind in the treatment of Leukemia. His top areas of expertise are Follicular Lymphoma, Non-Hodgkin Lymphoma, Acute Myeloid Leukemia (AML), and Leukemia.

His clinical research consists of co-authoring 144 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 72 articles and participated in 1 clinical trial in the study of Leukemia.

Gender
Male

Locations

Xiamen, China
Other Locations
Fuzhou, 351002, China
Dalian, 116029, China
Guangzhou, 510515, China
Shenzhen, 518055, China
Nanfang, 510515, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Multi-center, Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of HMPL-689 in Patients With Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
A Multi-center, Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of HMPL-689 in Patients With Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Drug
Study Drug: HMPL-689
Study Phase: Phase 2
Observational, Non-interventional, Multicenter Study Aimed at Collecting Prospective Data Related to Study Safety and Effectiveness in Real Clinical Practice in Patients With CD30+ Lymphoma (BRAVE Study)
Observational, Non-interventional, Multicenter Study Aimed at Collecting Prospective Data Related to Study Safety and Effectiveness in Real Clinical Practice in Patients With CD30+ Lymphoma (BRAVE Study)
Enrollment Status: Active_not_recruiting
Publish Date: January 27, 2025
Intervention Type: Other
A Multicenter, Open-label, Phase 1/2a Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
A Multicenter, Open-label, Phase 1/2a Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Enrollment Status: Completed
Publish Date: April 15, 2024
Intervention Type: Drug
Study Drugs: TJ011133, Azacitidine
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trials

144 Total Publications

Automated Configuration of Evolutionary Algorithms via Deep Reinforcement Learning for Constrained Multiobjective Optimization.
Automated Configuration of Evolutionary Algorithms via Deep Reinforcement Learning for Constrained Multiobjective Optimization.
Journal: IEEE transactions on cybernetics
Published: September 05, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Xu's expertise for a condition
ConditionClose
    View All 7 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile